r/r Hodgkin Lymphoma, CD30, adult, pediatrics
Showing 1 - 25 of >10,000
Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)
Not yet recruiting
- Relapsed or Refractory Hodgkin Lymphoma
- Peripheral T Cell Lymphoma
- AFM13
- +4 more
- (no location specified)
May 30, 2023
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)
Recruiting
- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma
- CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital
Nov 19, 2023
Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory Trial in United States (CD30.CAR-T, Fludarabine,
Active, not recruiting
- Hodgkin Lymphoma, Adult
- +3 more
- CD30.CAR-T
- +2 more
-
Duarte, California
- +4 more
Apr 3, 2022
B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)
Recruiting
- B-Cell Non Hodgkin Lymphoma
- B-Cell Acute Lymphoblastic Leukemia
- anti-CD19 CAR T-cells
-
Hanoi, VietnamVinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)
Not yet recruiting
- Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
- (no location specified)
Mar 23, 2023
Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin Trial in Ribeirao Preto (CART-19)
Not yet recruiting
- Leukemia, Acute Lymphoblastic
- Lymphoma, Non-Hodgkin
- CART-19
-
Ribeirao Preto, Sao Paulo, BrazilRibeirao Preto School of Medicine, University of Sao Paulo
Oct 23, 2023
Non-Hodgkin Lymphoma Trial in Aurora (CD19x22 CAR T Cells)
Active, not recruiting
- Non-Hodgkin Lymphoma
- CD19x22 CAR T Cells
-
Aurora, ColoradoUniversity of Colorado Hospital
Sep 1, 2022
Advanced Malignancies Trial in Beijing (1A46 Drug Substance)
Not yet recruiting
- Advanced Malignancies
- 1A46 Drug Substance
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Aug 4, 2023
Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),
Not yet recruiting
- Non Hodgkin's Lymphoma
- TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
- +2 more
-
Beijing, China
- +2 more
Aug 23, 2023
Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory Trial in United States
Completed
- Non-Hodgkin's Lymphoma, Relapsed
- +8 more
- PBCAR20A
- +2 more
-
Duarte, California
- +4 more
Jan 4, 2023
Non Hodgkin's Lymphoma Trial in Beijing (Allogenic CD19-CAR-?dT cell, Fludarabine, Cyclophosphamide)
Recruiting
- Non Hodgkin's Lymphoma
- Allogenic CD19-CAR-γδT cell
- +2 more
-
Beijing, Beijing, China
- +1 more
Jan 31, 2023
Non-hodgkin Lymphoma,B Cell Trial (CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection)
Not yet recruiting
- Non-hodgkin Lymphoma,B Cell
- CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection
- (no location specified)
Feb 14, 2023
Non Hodgkin Lymphoma Trial in Aurora (UCD19 CAR T Cells)
Active, not recruiting
- Non Hodgkin Lymphoma
- UCD19 CAR T Cells
-
Aurora, ColoradoUniversity of Colorado Hospital
Sep 1, 2022
Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Tampa (Comprehensive Ablative Bridging Irradiation (CABI),
Recruiting
- Large B-cell Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- Comprehensive Ablative Bridging Irradiation (CABI)
- Chimeric Antigen Receptor T-Cell Therapy
-
Tampa, FloridaMoffitt Cancer Center
Oct 26, 2023
B-cell Non Hodgkin Lymphoma Trial in Xuzhou (regimen with BTK inhibitor +Anti-CD19 CAR T cells)
Recruiting
- B-cell Non Hodgkin Lymphoma
- regimen with BTK inhibitor +Anti-CD19 CAR T cells
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023
Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)
Recruiting
- Non-hodgkin Lymphoma,B Cell
- Autologous CD19-STAR-T cell
- +2 more
-
Beijing, Beijing, China
- +1 more
Nov 21, 2022
Acute T-lymphoblastic Leukemia, Acute T-lymphoblastic Lymphoma Trial in Xuzhou (CAR-T Cell Infusion)
Recruiting
- Acute T-lymphoblastic Leukemia
- Acute T-lymphoblastic Lymphoma
- CAR-T Cell Infusion
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023
Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed
Not yet recruiting
- Pediatric Cancer
- +11 more
- anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
-
Milwaukee, WisconsinChildren's Wisconsin
Sep 14, 2022
B-cell Non-Hodgkin's Lymphoma Trial (IMM0306, Lenalidomide capsule)
Not yet recruiting
- B-cell Non-Hodgkin's Lymphoma
- IMM0306
- Lenalidomide capsule
- (no location specified)
Mar 6, 2023
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in United States (IMPT-314)
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
-
Los Angeles, California
- +3 more
Apr 12, 2023
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Fairway, Houston (SC291)
Recruiting
- Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
-
Fairway, Kansas
- +1 more
May 30, 2023
Relapase and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells Trial in Beijing
Recruiting
- Relapase and Refractory B-cell Non-Hodgkin's Lymphoma
- Decitabine-primed Tandem CD19/CD20 CAR T Cells
- Decitabine-primed Tandem CAR19/20 engineered T cells
-
Beijing, Beijing, ChinaBiotherapeutic Department of Chinese PLA General Hospital
Mar 24, 2022
Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,
Completed
- Grade 3a Follicular Lymphoma
- +9 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2023